Biogen (BIIB) Q3 FY26 earnings call

Biogen's strategic transition advanced materially in Q3 FY26 as revenue returned to double-digit expansion, led by commercial execution across the newly integrated complement franchise and core growth drivers. While legacy headwinds and Part D formulary pressures temper mature lines, operational integration pace and pipeline momentum support sustainable top-line expansion.